SR9009

无

SR9009 is a REV-ERB agonist that increases the constitutive repression of genes regulated by REV-ERBα and REV-ERBβ with IC50 values of 670 and 800 nM, respectively.1 Through activation of REV-ERB, SR9009 has been shown to decrease circadian locomotor activity during the dark phase and to alter the expression pattern of core clock genes in the hypothalami of mice.1 The circadian pattern of expression of an array of metabolic genes in the liver, skeletal muscle and adipose tissue was also shown to be altered in mice exposed to SR9009, resulting in increased energy expenditure.1 Diet-induced obese mice treated with 100 mg/kg SR9009 (i.p. two times a day for 30 days) have been reported to display decreased fat mass and markedly improved dyslipidemia and hyperglycemia.1WARNING This product is not for human or veterinary use.

A REV-ERBα/β agonist

437.9

≥98%

Biochemicals/Receptor Pharmacology/Agonists

Formal_Name:3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-1-pyrrolidinecarboxylic acid ethyl ester;Synonyms:REV-ERB Agonist II

ClC(C=C1)=CC=C1CN(CC2CCN(C(OCC)=O)C2)CC3=CC=C([N+]([O-])=O)S3

C20H24ClN3O4S

1379686-30-2

≥ 4 years

DMF: 30 mg/ml DMSO: 30 mg/ml Ethanol: 14 mg/ml

1.Solt, L.A.,Wang, Y.,Banerjee, S., et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485, 62-68 (2012).